Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB0025 with or without HB0030 in advanced solid tumors
CTR20240719Phase 2Suspended
- Sponsor
- Huabo Biopharm
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of sotiburafusp alfa and HB0030 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC) (3 arms), sponsored by Huabo Biopharm. Primary endpoints: Safety, Dose-limiting toxicity and maximum tolerated dose and 2 more. Started Apr 2024; status: suspended.
02
Drugs
sotiburafusp alfaHB0030
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20240719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240719.